Troutman Pepper advised Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, in its acquisition of Custopharm Inc. from Water Street Healthcare Partners, following approval from the U.S. Federal Trade Commission. Read a company press release about the acquisition.
The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline and expands Hikma’s differentiated U.S. portfolio to nearly 130 commercialized injectable medicines – a more than fivefold increase over the last decade.
The Troutman Pepper team advising Hikma in the acquisition was led by Chris Miller and included Barbara Sicalides, Erin Whaley, Judy O’Grady, Samantha Peruto, Sarah Rust Plyant, Ryan Salem, and Kahn Wiedis, among others.